Design paper for a single-centre, double-blind trial of clazakizumab, an IL-6 inhibitor, versus placebo for 24 weeks in adults aged 70+ with low to moderate physical function and raised IL-6; primary outcome is 400 m walking speed. No results yet.
RCT
Sattui et al. The "Reducing Inflammation for Greater Health Trial (RIGHT)" Study-Concept, Rationale, and Design